Sanofi (SNY) FCF Margin (2009 - 2026)

Sanofi (SNY) posted FCF Margin of 25.52% for Q2 2026, up 59.38% sequentially from 16.01% in Q1 2026, and up 1090.0% YoY from 2.14% in Q2 2025.

Sanofi (SNY) FCF Margin (2009 - 2026) Analysis & Trends

Sanofi has reported FCF Margin for 9 years, with the latest figure at 25.52% in Q2 2026.

Quarterly FCF Margin rose 1090.0% year-over-year to 25.52% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 47.01% (down 650.0% YoY) and the FY2025 annual result came in at 16.53%, up 220.0% from the prior year.
FCF Margin improved to 25.52% in Q2 2026 per SNY's latest filing, from 16.01% in the prior quarter.
Over five years, FCF Margin peaked at 152.8% in Q4 2024 and troughed at 112.44% in Q4 2025.
A 5-year average of 23.3% and a median of 22.6% in 2025 frame the typical range for FCF Margin.
The sharpest annual moves came in 2024 and 2025: FCF Margin surged 12338 bps in 2024, then tumbled 26524 bps in 2025.
Over 5 years, FCF Margin stood at 34.0% in 2022, then dropped by 13 bps to 29.41% in 2023, then soared by 419 bps to 152.8% in 2024, then sank by 174 bps to 112.44% in 2025, then jumped by 123 bps to 25.52% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 25.52%, 16.01%, and 112.44% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	28.82%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	18.33%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	26.96%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	38.60%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	-12.07%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	34.70%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	44.00%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	2.01%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	3.90%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	18.92%

Download Data